| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c8ed020d9d1eed3acfa2285b2f55de30 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2570-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-085 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-743 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 |
| filingDate |
2021-01-29^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33b3d89d8d9c683c2ecce504809f0436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f223f0fd0e7f1d9b8fb4f37162c842c |
| publicationDate |
2022-12-07^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-4097487-A1 |
| titleOfInvention |
Biomarkers |
| abstract |
A method of diagnosing non-alcoholic fatty liver disease (NAFLD) in a subject, and/or determining the stage of NAFLD in a subject diagnosed with NAFLD; or a method of identifying a subject having an increased risk of developing liver cancer; or a method of treating a subject with NAFLD having advanced fibrosis or cirrhosis; wherein the method comprises determining the level of at least one steroid hormone or metabolite thereof in a urine sample provided by the subject. |
| priorityDate |
2020-01-31^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |